Las Vegas, NV, Aug. 04, 2022 (GLOBE NEWSWIRE) — Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on the development of unique and lifesaving medicines products, is pleased to announce the launch of its new innovative corporate website: https://www.odysseyhealthinc.com/. The company’s new website, much like the previously announced company name change, was designed to not only better reflect Odyssey Health’s mission and direction, but also to improve communication strategies with current/potential shareholders, institutions and various scientific and financial publications.
The company has also released the latest corporate presentation, which is available on its newly launched website at https://www.odysseyhealthinc.com/investor-relations.
“The launch of our new website is an important next step in the continued evolution of Odyssey and will enable us to provide more transparent communications with our shareholders and other stakeholders,” commented Michael Redmond, CEO of Odyssey Health. “We are excited to provide visitors to our website with an optimal user experience that facilitates seamless access to the information they need through a well-designed interface while enhancing the Odyssey brand. We remain committed to providing timely and easily accessible updates not only through our website, but on all of our corporate social media platforms, as we continually work on our research, as well as to spread the important message about the need to treat concussions worldwide. ”
We encourage our shareholders to visit: https://www.odysseyhealthinc.com/ or our corporate social media platforms:
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Group International, Inc. (OTC: ODYY) is a technology and asset acquisition company specializing in life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have identified technological advantage, offer superior clinical utility, have substantial market opportunity and deliver strong returns to its valued shareholders and partners.
PRV-002 is a fully synthetic unnatural neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 demonstrated equivalent, if not superior, neuroprotective effects when compared to related neurosteroids. Animal models of concussion have demonstrated that PRV-002 reduces behavioral pathology associated with brain injury symptoms such as impaired memory, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress, and inflammation in the brain while restoring healthy blood circulation.
This press release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on our current expectations and speak only as of the date hereof. . Our actual results may differ materially and adversely from those expressed in forward-looking statements due to various factors and uncertainties, including our ability to continue to raise necessary funds, to successfully complete the Phase I trial, our ability to develop success of products, rapid changes in our markets, changes in demand for our future products, changes in legislation, regulations, competition and general economic conditions.
E-mail: [email protected]
Odyssey Health, Inc. Launches New Corporate Website